Promising treatment for dogs with CKD shows positive results
Pariacalcitol is a type of vitamin D and is believed to be a positive way to manage CKD complications.
Fierce Biotech9d
AstraZeneca's $800M rare disease bet hits primary phase 3 goal, but competitive strength still unclear
A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...
Potential treatment for chronic kidney disease in dogs developed
A new study led by Dr. Hilla Chen from the Koret School of Veterinary Medicine at Hebrew University, recently published in ...
Healthline6d
Treatment Options for Hypoparathyroidism
There’s no cure for hypoparathyroidism, but treatment options like calcium supplements, diuretics, and parathyroid hormone therapy can help regulate your calcium and phosphate levels.
AstraZeneca announces eneboparatide met primary endpoint in Phase III trial
High-level results from the CALYPSO Phase III trial showed that eneboparatide, AZP-3601, an investigational parathyroid hormone receptor 1 ...
Researchers Test New Treatment for Kidney Disease in Dogs
The study, published in the Journal of Veterinary Internal Medicine, examined the effects of paricalcitol -- a synthetic form ...
Eventful Monday For AstraZeneca - What's Going On?
AstraZeneca Plc (NASDAQ:AZN) released high-level results from the CALYPSO Phase 3 trial designed to evaluate the efficacy and ...
EurekAlert!6d
Potential treatment for chronic kidney disease in dogs revealed
A new study led by Dr. Hilla Chen, Prof. Gilad Segev and Dr. Michal Mazaki-Tovi from the Koret School of Veterinary Medicine ...